Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CPP FINALS > CHEMO > Flashcards

CHEMO Flashcards

1
Q

Cyclophosphamide

A

An alkylating agent, Administration by mouth or intravenously

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cyclophosphamide

A

A urinary metabolite of cyclophosphamide, acrolein, may cause hemorrhagic cystitis and so advise patient to increase fluid intake for 24–48 hours after administration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Antimetabolites

A
  1. Methotrexate
  2. Capcetabine
  3. Premetrexed and ralitrexed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Methotrexate

A

It has a folate-antagonist action and folinic acid (calcium folinate) is used to counteract this

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Capecitabine

A

Metabolised to fluorouracil, an antimetabolite drug that is administered by intravenous injection since oral administration of fluorouracil is associated with unpredictable absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pemetrexed and ralitrexed

A

Inhibit thymidylate transferase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pemetrexed

A

used in lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ralitrexed

A

used in colorectal carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Vinca Alkaloids

A

ause neurological toxicity: peripheral or autonomic neuropathy that is manifested as a tingling sensation and with constipation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

vincristine

A

Myelosuppression occurs to a lesser extent with _____

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cytotoxic Antibiotics

A

BDLL

  1. Blemoycin
  2. Doxorubicin, daunorubicn
  3. Liposomal formulations of doxorubicin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bleomycin

A

May cause hyperpigmentation and progressive pulmonary fibrosis, which is manifested as breathlessness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Doxorubicin, daunorubicin

A

May cause cardiomyopathy; monitor for occurrence of breathlessness, tiredness and malaise.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Liposomal formulations of doxorubicin

A

Long-circulating pegylated liposomal formulation which is comparable in efficacy to doxorubicin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Liposomal formulations of doxorubicin

A

occurrence of hand–foot syndrome (painful, macular, reddening skin eruptions) after two to three treatment cycles. May be dose limiting. Prevention: cooling of hands and feet, avoid tight-fitting footwear for 4–7 days after treatment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Platinum Compounds

A

COC

A .Cisplatin, carboplatin and oxaliplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cisplatin, carboplatin and oxaliplatin

A

Commonly used for ovarian cancer and testicular teratoma

17
Q

Cisplatin, carboplatin and oxaliplatin

A

Nephrotoxicity may occur: to avoid ensure pre-treatment hydration and prolonged hydration
with intravenous fluids, monitor kidney function

18
Q

Taxanes

A

Palcitaxel and docetaxel

19
Q

Palcitaxel and docetaxel

A

Used for ovarian cancer and secondary treatment for breast cance

20
Q

Topoisomerase I inhibitors

A

Irinotecan and topotecan

21
Q

Irinotecan and topotecan

A

Used for colorectal cancer and ovarian cancer respectively as a secondary line of treatment

22
Q

Irinotecan and topotecan

A

Gastrointestinal side-effects, particularly diarrhoea, and asthenia, alopecia and anorexia
may occur.

23
Q

Protein kinase inhibitors

A

Imatinib, dasatinib

24
Q

Imatinib, dasatinib

A

Tyrosine kinase inhibitors
Used in leukaemia
Available for oral administration.

25
Q

Erlotinib

A

A tyrosine kinase inhibitor that is available for oral administration; licensed for the treatment of pancreatic and lung cancer.

26
Q

Sunitinib

A

A tyrosine kinase inhibitor that is available for oral administration; licensed for the treatment of renal cell carcinoma.

27
Q

Sorafenib

A

An inhibitor of multiple kinases which is licensed for renal cell and hepatocellular carcinoma.

28
Q

Trastuzumab

A

For metastatic breast cancer with tumours overexpressing the human epidermal growth factor receptor 2 (HER-2)

29
Q

Trastuzumab

A

May be used in combination with paclitaxel

30
Q

OCCURRENCE OF SIDE EFFECTS

Immediate (Hours)

A

Phlebitis due to extravasation

31
Q

Immediate (Hours)

A

Nausea, vomiting

32
Q

Immediate (Hours)

A

Fever, chills

33
Q

Early (Days)

A

Diarrhea

34
Q

Early (Days)

A

Ototoxicity

35
Q

Early (Days)

A

SAM
Stomatitis
Alopecia
Myelotoxicity

36
Q

Delayed (Weeks)

A

Pulmonary Fibrosis

37
Q

Delayed (Weeks)

A

Peripheral neuropathy

38
Q

Delayed (Weeks)

A

Hyperpigmentation

Anemia

39
Q

Late (Months/Years)

A

Secondary malignancies

40
Q

Late (Months/Years)

A

Premature menopause

41
Q

Late (Months/Years)

A

Sterility

CPP FINALS (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions